Form 4: Cytosorbents CFO Peter J. Mariani Reports Acquisition of Common Stock and Warrants

Peter J. Mariani, CFO of Cytosorbents Corp, reports acquiring common stock and warrants through a rights offering.

Summary

• Peter J. Mariani, the Chief Financial Officer of Cytosorbents Corporation, filed a Form 4 detailing changes in beneficial ownership.
• On January 17, 2025, Mariani exercised subscription rights from a rights offering, acquiring 32,625 shares of common stock, Series A warrants, and Series B warrants at $1.00 per unit, totaling $32,625.
• The Series A warrants have an exercise price of $1.13.
• Following the reported transactions, Mariani directly owns 466,613 shares of common stock, which includes restricted stock units (RSUs) that vest upon specific conditions such as a change in control or the fourth anniversary of the grant date.
• The RSUs are settled into common stock upon vesting.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a routine transaction. The CFO's participation in the rights offering could be seen as a slightly positive signal.

Positives

• The CFO's participation in the rights offering demonstrates confidence in the company's future.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and assess management's alignment with shareholder interests.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder confidence due to the CFO's increased investment in the company.

Key Dates